Expiration date: 02/2029
Composition
One capsule contains:
Active ingredient: troxerutin 300 mg.
Excipients: lactose monohydrate 47 mg, magnesium stearate 3 mg.
Capsule shell: capsule body - quinoline yellow dye (E 104) 0.9%, sunset yellow dye (E 110) 0.039%, titanium dioxide (E 171) 3%, gelatin up to 100%, capsule lid - quinoline yellow dye (E 104) 0.9%, sunset yellow dye (E, 110) 0.039%, titanium dioxide (E 171) 3 %, gelatin up to 100%.
Dosage form
of the capsule
Description
Solid cylindrical gelatin capsules No. 1, the body is yellow, the lid is yellow.
Capsule contents: yellow to yellow-green powder, conglomerates are allowed, which disintegrate when pressed.
Pharmacodynamics
Angioprotective agent, acts mainly on capillaries and veins. It reduces the pores between endothelial cells by modifying the fibrous matrix located between endothelial cells.
It inhibits the aggregation and increases the degree of deformation of red blood cells, has an anti-inflammatory effect.
In chronic venous insufficiency, Troxevazine reduces the severity of edema, pain, seizures, trophic disorders, and varicose ulcers. Relieves the symptoms associated with hemorrhoids - pain, itching and bleeding.
Due to the beneficial effect of Troxevasin on the permeability and resistance of capillary walls, it helps slow down the development of diabetic retinopathy. In addition, its effect on the rheological properties of blood helps to prevent retinal vascular microthrombosis.
Pharmacokinetics
After oral administration, absorption is about 10-15%. The maximum plasma concentrations are reached on average 2 hours after ingestion, the therapeutic plasma level will remain for 8 hours. It is metabolized in the liver, partially excreted unchanged in the urine (20-22% of the dose taken) and bile (60-70% of the dose taken).
Indications for use
Chronic venous insufficiency, post-phlebitis syndrome, trophic disorders in varicose veins and trophic ulcers. As an auxiliary treatment after sclerosis of veins and removal of varicose veins.
Hemorrhoids (pain, exudation, itching and bleeding).
Venous insufficiency and hemorrhoids during pregnancy, starting from the second trimester.
As an auxiliary treatment of retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.
Contraindications
Hypersensitivity to rutosides or to other components of the drug. Pregnancy (I trimester). Peptic ulcer of the stomach and duodenum, chronic gastritis in the acute phase, children under three years of age (solid dosage form).
Use during pregnancy and lactation
Troxevazine should be used during pregnancy (II and III trimesters) and during lactation if the expected benefit to the mother outweighs the possible risk to the fetus and child.
Side effects
Allergic reactions (for example, skin rash), nausea, diarrhea, heartburn, headache, flushes of blood to the face, erosive and ulcerative lesions of the gastrointestinal tract. They disappear quickly after discontinuation of treatment.
Interaction
The effect is enhanced by taking ascorbic acid at the same time.
Method of administration and dosage
Inside, during meals, the capsules are swallowed whole, washed down with a sufficient amount of water. At the initial stage of treatment, 1 capsule (300 mg) is prescribed 3 times a day.
The effect usually develops within 2 weeks, after which the treatment is continued at the same dose or reduced to a minimum maintenance dose of 600 mg, or suspended (while the achieved effect persists for at least 4 weeks). The course of treatment averages 3-4 weeks, the need for longer treatment is determined individually.
For diabetic retinopathy, 0.9 - 1.8 g / day is prescribed.
Overdose
In case of overdose, the following symptoms may occur: agitation, nausea, headache, flushing of blood to the face. In case of overdose, patients should rinse their stomach, take activated charcoal, and, if necessary, begin symptomatic treatment.
Special instructions
If the severity of the symptoms of the disease does not decrease during the use of the drug, you should consult a doctor. There is insufficient experience of using the drug in children under 15 years of age, which requires caution when using it.
Influence on the ability to drive motor vehicles and manage mechanisms
Taking the drug has no effect on motor and mental reactions, does not interfere with driving vehicles and working with mechanisms.
Form of release
Capsules of 300 mg.
Packaging
10 capsules in a blister of PVC/Aluminum foil or PVC/PVDH/Al foil.
5 or 10 blisters together with the instructions for use in a cardboard pack.
Conditions of release from pharmacies
Without a prescription
Storage conditions
In a dry place protected from light, at a temperature not exceeding 25C.
Keep out of reach of children!
Shelf
life is 5 years.Do not use after the expiration date
